Clinical Trials
12 trialsNCT07610733 2026-05-28
IFOCOS
Fudan University
Phase 2 Not yet recruiting
NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT04576455 2026-03-20
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT03879577 2026-01-21
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Active not recruiting
NCT06001762 2026-01-16
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03944434 2025-02-26
FACILE
Fondazione Sandro Pitigliani
Phase 2 Active not recruiting
NCT05720260 2024-06-10
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
Phase 2 Recruiting
NCT05638594 2023-03-20
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Shengjing Hospital
Phase 2 Recruiting
NCT03058939 2019-04-22
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Withdrawn
NCT02592746 2019-04-08
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
Phase 2 Unknown
NCT03397537 2018-01-17
Neoadjuvant Endocrine Therapy in Breast Cancer
Guangdong Provincial People's Hospital
Phase 2 Completed